[{"id":"470758fd-4890-43eb-8652-e5ea7fb90204","acronym":"ENZENO","url":"https://clinicaltrials.gov/study/NCT04669587","created_at":"2021-01-19T20:44:20.806Z","updated_at":"2024-07-02T16:36:15.004Z","phase":"Phase 1/2","brief_title":"ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)","source_id_and_acronym":"NCT04669587 - ENZENO","lead_sponsor":"EnhancedBio USA Inc.","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • borestrant (ZB716)"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2022-03-22"}]